Investors & Media

Our Mission

To Harness the Power of Selectivity in Complement Therapeutics

We envision the full potential of complement therapeutics lies within the power of selectivity. Our lead antibody, DNTH103, is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology – enabling less frequent and more convenient self-administered subcutaneous injections to improve the lives of patients.